Document is current

Article History

Received: 27 September 2024

Accepted: 25 December 2024

First Online: 8 January 2025

Declarations

:

: All procedures performed in this study involving human participants were performed in accordance with the ethical standards of the institutional committee, as well as the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Institutional Review Board of Nippon Medical School Hospital (approval number: 220038). Clinical trial number: not applicable. All enrolled patients provided written informed consent.

: Not applicable.

: MM received lecture honoraria from Astra Zeneca(AZ), Chugai pharmaceutical, Taiho pharmaceutical, and Ono Pharmaceutical, AM received lecture honoraria from AZ, Nippon Kayaku, Merck, Kyowa, YM received lecture honoraria from AZ, Bristol-Myers Squibb company, Eli Lily, Takeda pharmaceutical co., Chugai Pharmaceutical, AG received lecture honoraria from Nippon Kayaku, Daiichisankyo, MS received honoraria from AZ, Chugai pharmaceutical, Taiho Pharmaceutical, Eli Lilly, Ono Pharmacetical, Bristol-Myers Squibb, Nippon Boehringer Ingelheim, Pfizer, Novartis, Takeda pharmaceutical, Kyowa Hakko Kirin, Nippon Kayaku, Daiichisankyo, Merck Biopharma, Amgen.